argenx SE (ARGX) stock
ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$960.04−21.29 (-2.17%)
Close on Nov 13, 2026Market cap –P/E 49.1Yield –
argenx r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $1.36B, up 38.7% from the year before. The highest annual figure on record is $1.36B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36B | +38.7% |
| FY2024 | Dec 31, 2024 | $983.42M | +14.4% |
| FY2023 | Dec 31, 2023 | $859.49M | +29.6% |
| FY2022 | Dec 31, 2022 | $663.37M | +14.3% |
| FY2021 | Dec 31, 2021 | $580.52M | +56.5% |
| FY2020 | Dec 31, 2020 | $370.89M | +68.0% |
| FY2019 | Dec 31, 2019 | $220.77M | +164.1% |
| FY2018 | Dec 31, 2018 | $83.61M | – |
See a number that looks wrong?